2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin Receptor

Related Products

PDF 2.76 MB

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0223
    Epibetulinic acid
    		Inhibitor ≥98.0%
    Epibetulinic acid exhibits potent inhibitory effects on NO and prostaglandin E2 (PGE2) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin with IC50s of 0.7 and 0.6 μM, respectively. Anti-inflammatory activity.
    Epibetulinic acid
  • HY-108557
    TCS 2510
    		Agonist ≥99.0%
    TCS 2510 is a selective EP4 agonist. TCS 2510 can be used for the research of metabolic diseases.
    TCS 2510
  • HY-P4160
    PDC31
    		Inhibitor 99.76%
    PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca2+-dependent large-conductance K+-channel in human myometrial cells.
    PDC31
  • HY-B0428B
    Ozagrel hydrochloride
    		Inhibitor 99.68%
    Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM.
    Ozagrel hydrochloride
  • HY-B1074
    Ethamsylate
    		Inhibitor 99.49%
    Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis..
    Ethamsylate
  • HY-108563A
    SC 51089 free base
    		Antagonist 98.64%
    SC 51089 free base is a selective antagonist of prostaglandin E2 EP1 receptor, with Kis of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 free base exhibits neuroprotective activity.
    SC 51089 free base
  • HY-145684
    EP2 receptor antagonist-1
    		Antagonist 99.45%
    EP2 receptor antagonist-1 (compound 1) is a potent, reversible, and agonist dependent allosteric prostaglandin EP2 receptor antagonist. EP2 receptor antagonist-1 shows anti-inflammatory effects.
    EP2 receptor antagonist-1
  • HY-118609
    EP4 receptor agonist 2
    		Agonist ≥99.0%
    EP4 receptor agonist 2 (compound 31) a potent EP4 receptor agonist with an EC50 value of 0.8 nM; Ki values of >100000, 38000, 3.1 nM for EP2, EP3, EP4 respectively.
    EP4 receptor agonist 2
  • HY-16751
    Ralinepag
    		Agonist 99.79%
    Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.
    Ralinepag
  • HY-130223
    11β-Prostaglandin E2
    		Inhibitor ≥99.0%
    11β-Prostaglandin E2 (11β-Dinoprostone), a Prostanoid derivative, inhibits [3H]PGE2 binding to hypothalamic membranes in the rat with a Ki of 53.3 nM.
    11β-Prostaglandin E2
  • HY-139419
    Bimatoprost grenod
    		Agonist 98.34%
    Bimatoprost grenod (NCX 470) is a second-generation nitric oxide (NO)-donating prostaglandin analogue. Bimatoprost grenod effectively lowers intraocular pressure (IOP) in animal models of ocular hypertension and glaucoma by activating bimatoprost-mediated uveoscleral outflow and NO mediated conventional outflow. Bimatoprost grenod can be used for the research of cular hypertension and glaucoma.
    Bimatoprost grenod
  • HY-19361
    L-826266
    		Antagonist ≥98.0%
    L-826266 is a selective and competitive EP3 receptor antagonist. L-826266 can be used for convulsive disorders research.
    L-826266
  • HY-114141
    BI-671800
    		Antagonist 99.36%
    BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2), with IC50 values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively. BI-671800 has potential for the treatment of poorly controlled asthma.
    BI-671800
  • HY-19998
    Taprenepag isopropyl
    		Agonist 99.23%
    Taprenepag isopropyl is a highly selective EP2 receptor agonist.
    Taprenepag isopropyl
  • HY-105005
    Crisdesalazine
    		Control 98.92%
    Crisdesalazine (AAD-2004) is an anti-inflammatory agent that simultaneously blocks inflammation mediated by free radicals and prostaglandin E2 (PGE2). Crisdesalazine (AAD-2004) can be used to study neurodegeneration in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
    Crisdesalazine
  • HY-142658A
    BAY-6672 hydrochloride
    		Antagonist 98.44%
    BAY-6672 hydrochloride is a potent and selective human Prostaglandin F (FP) receptor antagonist with an IC50 value of 11 nM.
    BAY-6672 hydrochloride
  • HY-118941
    BAY 73-1449
    		Antagonist 99.99%
    BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure.
    BAY 73-1449
  • HY-B0428A
    Ozagrel sodium
    		Inhibitor 99.98%
    Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.
    Ozagrel sodium
  • HY-12184
    ONO-AE 248
    		Agonist 98.27%
    ONO-AE 248 is a selective EP3 receptor agonist with cardioprotective activity. ONO-AE 248 reduces myocardial infarction size by selectively binding to the EP3α receptor in mice. The cardioprotective effect of ONO-AE 248 is independent of hemodynamic effects. The mechanism of ONO-AE 248 may involve activation of protein kinase C and opening of K(ATP) channels.
    ONO-AE 248
  • HY-15853
    MK-7246
    		Antagonist 99.63%
    MK-7246 is a potent and selective CRTH2 antagonist with a Ki of 2.5±0.5 nM.
    MK-7246
Cat. No. Product Name / Synonyms Application Reactivity
Prostaglandin Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.